VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 464 filers reported holding VALEANT PHARMACEUTICALS INTL in Q3 2014. The put-call ratio across all filers is 1.12 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $3,357,000 | +150.1% | 231,179 | +322.8% | 0.08% | +159.4% |
| Q3 2016 | $1,342,000 | -31.7% | 54,679 | -44.0% | 0.03% | -22.0% |
| Q2 2016 | $1,966,000 | +142.4% | 97,627 | +216.7% | 0.04% | +78.3% |
| Q1 2016 | $811,000 | -24.8% | 30,824 | +190.3% | 0.02% | +27.8% |
| Q4 2015 | $1,079,000 | -83.6% | 10,618 | -71.2% | 0.02% | -83.3% |
| Q3 2015 | $6,580,000 | +44.2% | 36,890 | +79.6% | 0.11% | +31.7% |
| Q2 2015 | $4,563,000 | +552.8% | 20,541 | +483.6% | 0.08% | +485.7% |
| Q1 2015 | $699,000 | +183.0% | 3,520 | +105.1% | 0.01% | +250.0% |
| Q4 2014 | $247,000 | -14.8% | 1,716 | -22.5% | 0.00% | -33.3% |
| Q3 2014 | $290,000 | -93.6% | 2,214 | -93.6% | 0.01% | -89.5% |
| Q1 2014 | $4,562,000 | +6.9% | 34,599 | -4.8% | 0.06% | +21.3% |
| Q4 2013 | $4,267,000 | -93.4% | 36,346 | -94.2% | 0.05% | -94.3% |
| Q3 2013 | $65,082,000 | – | 623,817 | – | 0.83% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 5,577,892 | $994,984,000 | 31.62% |
| Ruane, Cunniff & Goldfarb | 33,922,192 | $6,051,041,000 | 31.06% |
| LeVasseur Capital Partners LLC | 162,394 | $28,968,000 | 29.76% |
| FARLEY CAPITAL L.P. | 192,130 | $34,272,000 | 27.18% |
| Pershing Square Capital Management | 19,473,933 | $3,473,760,000 | 24.90% |
| Arrow Capital Management, LLC | 109,461 | $19,525,000 | 16.53% |
| Marble Arch Investments | 1,196,900 | $213,503,000 | 16.43% |
| Tesuji Partners | 1,368,040 | $244,414,000 | 15.82% |
| ValueAct Holdings | 14,994,261 | $2,674,676,000 | 15.55% |
| Hound Partners | 3,898,648 | $695,441,000 | 15.04% |